Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study.
BACKGROUND In 2023, novel oral polio vaccine type 2 (nOPV2) was used to respond to an outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Kenya. We assessed the immunogenicity of one and two doses of nOPV2 administered during outbreak response. METHODS An observational cohort study was conducted fro...